Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10100 Turin, Italy.
Int J Mol Sci. 2021 Jul 12;22(14):7457. doi: 10.3390/ijms22147457.
Cognitive impairment is currently considered a core feature of schizophrenia (SZ) and is gaining attention as a fundamental therapeutic target. Standard treatment for SZ involves the use of antipsychotics that are successfully used to control positive symptoms and disorganized behaviour. However, it is still unclear whether they are effective on social cognition (SC) impairment. Furthermore, different medications are currently being studied to improve SC in patients with SZ. A literature search on this topic was conducted using the PubMed database. All kinds of publications (i.e., reviews, original contributions and case reports) written in English and published in the last 15 years were included. The aim of our literature review is to draw a picture of the current state of the pharmacological treatment of SC impairment in SZ.
认知障碍目前被认为是精神分裂症（SZ）的核心特征，并且作为一个基本的治疗靶点受到关注。SZ 的标准治疗包括使用抗精神病药物，这些药物成功地用于控制阳性症状和紊乱行为。然而，目前尚不清楚它们是否对社会认知（SC）障碍有效。此外，目前正在研究不同的药物来改善 SZ 患者的 SC。使用 PubMed 数据库对该主题进行了文献检索。纳入了过去 15 年发表的各种出版物（即综述、原始贡献和病例报告），均为英文撰写。我们文献综述的目的是描绘 SZ 中 SC 损害的药物治疗现状。
